[1]Zhang, Hanbo et al.(2021).PSMA Theranostics: CurrentLandscape and Future Outlook.Cancers.doi:10.3390/cancers13164023 [2]Ng TSC,et al.(2021)IncorporatingPSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment:aMultidisciplinary Perspective.FrontOncol.doi:10.3389/fonc.2021.722277 [3]Czerw...
[1]Zhang, Hanbo et al.(2021).PSMA Theranostics: CurrentLandscape and Future Outlook.Cancers.doi:10.3390/cancers13164023 [2]Ng TSC,et al.(2021)IncorporatingPSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment:...
[1]Zhang, Hanbo et al.(2021).PSMA Theranostics: CurrentLandscape and Future Outlook.Cancers.doi:10.3390/cancers13164023 [2]Ng TSC,et al.(2021)IncorporatingPSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment:aMultidisciplinary Perspective.FrontOncol.doi:10.3389/fonc.2021.722277[3]Czerwi...
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal transduction and targeted therapy, 2022, 7(1): 198. doi:10.1038/s41392-022-01042-7. [3] Hennrich U, Eder M. [177Lu] Lu-PSMA-617 (PluvictoTM): The First FDA-approved radiotherapeutical for treatment ...
as measured by the DSC and PPV at the voxel level. The resulting segmentations can be used for extraction of PET-derived quantitative biomarkers and utilized for treatment response assessment and radiomic studies. Keywords Prostate cancer · [68Ga]Ga-PSMA · PET/CT · Deep learning · Artifcial...
原文出处:Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer 免责声明:本文仅作信息交流,文中的观点不代表中肽生化立场,亦不代表中肽生化支持或反对文中观点。本文也不构成投资建议,也不是研究治...
[2]Ng TSC,et al.(2021)IncorporatingPSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment:aMultidisciplinary Perspective. FrontOncol .doi:10.3389/fonc.2021.722277 [3]Czerwińska, M.et al.(2020).TargetedRadionuclide Therapy of Prostate Cancer-From Basic Research to ClinicalPerspectives. ...
[5]Gafita A, Rauscher I, Weber M, et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study[J]. J Nucl Med, 2022, 63: 1651-1658. ...
此外,诺华也正在评估Pluvicto用于前列腺癌早期治疗的机会。 原文链接:https://www.novartis.com/news/media-releases/novartis-pluvictotm-approved-fda-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer...
参考来源：Novartis Pharma AG；Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer；March 23, 2022 16:19 ET 注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。